Notification
No new Notification messages
Niva Bupa Health Insurance IPO is Open!
Apply for the Niva Bupa Health Insurance IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Diwali Offer: MTF at just 9.99%
Iss Diwali, Investments Ko Karo 4X with our Trade Now, Pay Later (MTF) feature
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Glenmark Pharma Sells Stake in Glenmark Life Sciences

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Glenmark Pharmaceuticals is to divest a 7.85% stake in Glenmark Life Sciences via an OFS on July 11-12, 2024, to meet SEBIi's public shareholding norms. The floor price is set at ₹810 per share, marking a 7.85% discount from the last closing price.

Glenmark Pharmaceuticals and Glen Saldanha, promoters of Glenmark Life Sciences, have announced plans to divest up to a 7.85% stake in the company through an Offer for Sale (OFS). This move aims to meet the minimum public shareholding requirements mandated by SEBI.

Explore: GLENMARK PHARMACEUTICALS

Offer for Sale Details

The promoters will offer up to 96.17 lakh shares of Glenmark Life Sciences during the OFS scheduled for July 11 and 12, 2024. The floor price for the OFS is set at ₹810, representing a 7.85% discount to Wednesday's closing price.

The OFS will be available to non-retail investors on Thursday, while retail investors can place their bids on Friday. A minimum of 10% of the OFS is reserved for retail investors, subject to valid bids.

Compliance with SEBI Regulations

As of March 31, 2024, promoters held an 82.85% stake in Glenmark Life Sciences. SEBI requires all listed companies to ensure that at least 25% of their equity shares are held by non-promoters.

Companies newly listed on the stock exchange have three years from their listing date to comply with this regulation. Glenmark Life Sciences, listed in August 2021, is approaching the deadline for compliance.

Previous Stake Sale to Nirma

In the previous year, Glenmark Pharmaceuticals sold 75% of its stake in Glenmark Life Sciences to Nirma at ₹615 per share, totalling ₹5,650 crores. This transaction significantly reduced its stake in Glenmark Life Sciences.

Board Approval for OFS

On July 10, 2024, Glenmark Pharmaceuticals' Board of Directors approved the sale of up to 96,09,571 equity shares of Glenmark Life Sciences, representing 7.84% of the company's issued and paid-up equity share capital. The sale will be conducted through the stock exchange mechanism in accordance with applicable laws.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text